Icahn School Of Medicine At Mount Sinai

Icahn School of Medicine at Mount Sinai's Financial Division Fund Accounting Division is a tax-exempt educational institution and premier academic medical center operating as a prime recipient and contractor delivering biomedical research, specialized clinical services, and educational programs to federal agencies across the NIH, VA, and DoD. The institution competes predominantly in full-and-open procurements without set-asides, with a recent award footprint spanning 4,467 federal transactions (3,589 prime, 878 sub) valued at $1.67 billion in potential value and $11.16 billion in obligations.

The capability portfolio centers on federally funded research and clinical services. Recent prime work includes a $18.5 million five-year NIH NeuroBank contract (awarded November 2025) to establish and operate a brain tissue repository for neuroscience research, involving acquisition, processing, storage, curation, and distribution of CNS tissue for approximately 350 to 1,000 donors annually; a $1.35 million Defense Health Agency cooperative agreement for the LIVEWELL Brain Health Study (awarded September 2025) investigating cognitive and psychological wellness interventions for individuals with violence-related traumatic brain injury; a $7.69 million DHA four-year award for LIVEWELL with sub-recipients at the University of Utah, Massachusetts General Hospital, and University of Washington delivering neuroimaging analysis, community engagement, and postmortem tissue characterization; and a $1.25 million VA educational cost contract with VISN 2 for clinical services supporting the Bronx VAMC extending through June 2031. The institution also holds a single-award indefinite delivery contract with VA VISN 4 (ceiling $298,000, through June 2027) for MRI scans, research services, and academic affiliate support, with recent delivery orders for specialized imaging and research support in the Bronx.

Customer concentration remains heavily weighted toward the National Institutes of Health. The NIH accounts for approximately 48% of award count (853 awards across all institutes), with the National Institute of Allergy and Infectious Diseases leading at 379 awards and $555.6 million combined potential value. The National Institute on Aging (332 awards), National Cancer Institute (317 awards, $2.8 million potential value), and National Institute of Mental Health (276 awards, $15.9 million potential value) round out the top five by count, while the National Institute of Child Health and Human Development ranks second in dollar value at $106.1 million across 77 awards. By potential value, NIAID maintains dominance at $555.6 million, followed by NICHD at $106.1 million, NIDDK at $44.7 million, NIDA at $40.4 million, and NHLBI at $32.3 million. The institution serves 110 distinct customer agencies, indicating broad federal portfolio penetration.

Activity has grown substantially. Awards per year rose from 237 in 2022 to 503 in 2024, though 2025 moderated to 444 and 2026 year-to-date shows 166 awards. Within the next twenty-four months, 438 awards with combined potential value of $311.1 million reach completion and face recompete. SCI-reported invoiced revenue (federal service contracts above the $150,000 threshold) totaled $218.1 million across FY2022–FY2024: $69.9 million in FY2022 across 397 FTEs, $69.8 million in FY2023 across 359 FTEs, and $78.4 million in FY2024 across 397 FTEs. Government-paid hourly rates on prime service contracts ranged from a 10th percentile of $66.33/hr to a median of $97.30/hr and a 90th percentile of $244.69/hr, reflecting heterogeneous labor categories from support staff to senior clinical and research personnel. Across SCI-reportable prime contracts, subcontractors performed approximately 20% of total hours, with 140 named subcontractors engaged across the portfolio.

The institution operates predominantly as a prime recipient and research performer; 80% of awards are prime positions. Subcontract work is performed under major academic research consortia and cooperative agreements where Mount Sinai serves as a research site or laboratory contributor, including roles as sub-recipient to Jackson Laboratory, Northwestern University, the University of Pennsylvania, Duke University, and Columbia University on NIH R01 and U19 grants. Named sub-awardees from the Financial Division include Oregon State University (peptide-conjugated phosphorodiamidate morpholino oligomer synthesis and characterization for Powassan and Nipah virus research), the University of Pennsylvania (HIV milk antibody characterization), Children's Hospital of Philadelphia (transferrin receptor studies in myelodysplastic syndrome), and Virginia Tech (pig model housing and immune sampling for vaccine development), indicating specialized roles in multi-site translational and clinical research networks. The institution does not compete as a subcontractor on federal contracts; its sub-engagement appears exclusively within cooperative research agreements where complementary scientific expertise is required.

Headquartered in New York, NY, the institution maintains work performance across multiple internal locations (Bronx, New York, and other New York City metropolitan sites) and serves as a fiscal and scientific leader in biomedical research funded by the NIH Blueprint for Neuroscience, the Defense Health Agency's Military Medical Research and Development program, and the VA's clinical partnership network. The breadth and depth of the portfolio—spanning basic neuroscience, immunology, infectious disease, cancer biology, cardiovascular research, and pediatric health across five major NIH institutes and the Defense and Veterans Affairs departments—positions the institution as a mission-critical federal research performer and clinical service provider for both civilian and military health innovation.